Cyclooxygenase-2 expression in invasive transitional cell carcinoma of the urinary bladder

  • Authors:
    • Yoshiaki Yamada
    • Kogenta Nakamura
    • Yasusuke Inoue
    • Katsuya Naruse
    • Shigeyuki Aoki
    • Tomohiro Taki
    • Motoi Tobiume
    • Kenji Zennami
    • Remi Katsuda
    • Kouji Hara
    • Inbou Kyoku
    • Noriko Mitsutake
    • Maki Arakawa
    • Hiroko Saito
    • Takaaki Hasegawa
    • Hiroshi Noguchi
    • Nobuaki Honda
  • View Affiliations

  • Published online on: November 1, 2008     https://doi.org/10.3892/mmr_00000030
  • Pages: 791-795
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Cyclooxygenase-2 (COX-2) activity is reported to increase apoptosis, inhibit angiogenesis and reduce metastasis. We analyzed COX-2 expression in patients with invasive bladder cancer to evaluate the feasibility of selective COX-2 inhibitor treatment targeting COX-2. Forty patients with pathologically diagnosed invasive transitional cell carcinoma of the urinary bladder (pT2-pT4) were evaluated. Immunohistochemical staining was used to evaluate COX-2 expression, and cases with staining of ≥10% of tumor cells were defined as positive. In 2 patients, 0% of the primary tumors stained for COX-2, while 1-5% was stained in 16 patients, 5-10% in 3 patients and ≥10% in 19 patients (19/40, 47.5%). In terms of grade, 2 patients with grade 2 (2/3, 66.6%) and 17 patients with grade 3 (17/37, 45.4%) were COX-2 positive. When categorized by stage, 11 patients with pT2 (11/22, 50.0%), 6 with pT3 (6/13, 46.1%) and 2 with pT4 (2/5, 40.0%) were positive. Lymph node metastasis was observed in 10 patients; 2 of them, with pN2, were COX-2 positive. Those with COX-2-positive metastatic lymph nodes had grade 3 primary tumors, which were also COX-2 positive. In addition, COX-2-negative metastatic lymph node patients also had negative primary tumors. The results of this study suggest that 47.5% of patients with invasive bladder cancer may benefit from treatment with selective COX-2 inhibitors targeting COX-2, and that treatment efficacy can be expected in patients with lymph node metastasis when their primary tumors are COX-2 positive.

Related Articles

Journal Cover

November 2008
Volume 1 Issue 6

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yamada, Y., Nakamura, K., Inoue, Y., Naruse, K., Aoki, S., Taki, T. ... Honda, N. (2008). Cyclooxygenase-2 expression in invasive transitional cell carcinoma of the urinary bladder. Molecular Medicine Reports, 1, 791-795. https://doi.org/10.3892/mmr_00000030
MLA
Yamada, Y., Nakamura, K., Inoue, Y., Naruse, K., Aoki, S., Taki, T., Tobiume, M., Zennami, K., Katsuda, R., Hara, K., Kyoku, I., Mitsutake, N., Arakawa, M., Saito, H., Hasegawa, T., Noguchi, H., Honda, N."Cyclooxygenase-2 expression in invasive transitional cell carcinoma of the urinary bladder". Molecular Medicine Reports 1.6 (2008): 791-795.
Chicago
Yamada, Y., Nakamura, K., Inoue, Y., Naruse, K., Aoki, S., Taki, T., Tobiume, M., Zennami, K., Katsuda, R., Hara, K., Kyoku, I., Mitsutake, N., Arakawa, M., Saito, H., Hasegawa, T., Noguchi, H., Honda, N."Cyclooxygenase-2 expression in invasive transitional cell carcinoma of the urinary bladder". Molecular Medicine Reports 1, no. 6 (2008): 791-795. https://doi.org/10.3892/mmr_00000030